Drugs / LNP-nCOV saRNA-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04934111 | Dec 2021 → Nov 2022 | COVID-19 | MRC/UVRI and LSHTM Uganda Research Unit | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNP-nCOV saRNA-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04934111 ↗ |
| Modality | Small activating RNA (saRNA) | “self-amplifying ribonucleic acid (saRNA) vaccine” NCT04934111 ↗ |
| Route | Intramuscular | “The vaccine is given by injection into the muscle of the upper arm.” NCT04934111 ↗ |